These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 1438438

  • 1. Effects of mafosfamide on the clonogenic cells in precursor B acute lymphoblastic leukemia: significance for ex vivo purging of bone marrow.
    Kramer B, Makrynikola V, Bradstock K.
    Prog Clin Biol Res; 1992; 377():41-7. PubMed ID: 1438438
    [No Abstract] [Full Text] [Related]

  • 2. Effect of mafosfamide (ASTA-Z-7654) on the clonogenic cells in precursor-B acute lymphoblastic leukaemia: significance for ex vivo purging of bone marrow for autologous transplantation.
    Makrynikola V, Kabral A, Bradstock KF.
    Bone Marrow Transplant; 1991 Nov; 8(5):351-5. PubMed ID: 1768969
    [Abstract] [Full Text] [Related]

  • 3. Effect of Ethiofos on cytotoxicity of pharmacological purging protocols used for autologous marrow grafts in acute lymphoblastic leukemia.
    Skala JP, Rogers PC, Chan KW, Rodriguez WC.
    Prog Clin Biol Res; 1992 Nov; 377():57-62. PubMed ID: 1332075
    [No Abstract] [Full Text] [Related]

  • 4. Effect of recombinant human stem cell factor on mafosfamide-treated bone marrow clonogenic cells.
    Carlo-Stella C, Mangoni L, Almici C, Caramatti C, Rizzoli V.
    Stem Cells; 1993 Jul; 11 Suppl 2():170-4. PubMed ID: 7691323
    [Abstract] [Full Text] [Related]

  • 5. The effect of a combined purging with mafosfamide and hyperthermia on murine haemopoietic stem cells and leukaemogenic cells.
    Gidáli J, Fehér I.
    Bone Marrow Transplant; 1992 Dec; 10(6):479-83. PubMed ID: 1490197
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Autologous BMT in high risk patients with CALLA-positive ALL: possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement.
    Morishima Y, Miyamura K, Kojima S, Ueda R, Morishita Y, Sao H, Tanimoto M, Ohno R, Sobue R, Hirano M.
    Bone Marrow Transplant; 1993 Apr; 11(4):255-9. PubMed ID: 7683550
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Evaluation of the protection of murine bone marrow stem cells by WR-2721 during in vitro treatment with mafosfamide.
    Jiang R, Bony V, Lopez M.
    Prog Clin Biol Res; 1994 Apr; 389():23-9. PubMed ID: 7700906
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. In vitro marrow purging in chronic myelogenous leukemia: effect of mafosfamide and recombinant granulocyte--macrophage colony-stimulating factor.
    Carlo-Stella C, Mangoni L, Piovani G, Almici C, Garau D, Caramatti C, Rizzoli V.
    Bone Marrow Transplant; 1991 Oct; 8(4):265-73. PubMed ID: 1756324
    [Abstract] [Full Text] [Related]

  • 13. Purging of acute lymphoblastic leukemia by long-term marrow culture.
    Douay L, Ozsahin H, Barbu V, Fabrega S, Giarratana MC, Da WM, Allieri A, Gorin NC.
    Prog Clin Biol Res; 1992 Oct; 377():205-13; discussion 214. PubMed ID: 1438417
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Plasma interacts with mafosfamide toxicity to normal haematopoietic progenitor cells: impact on in vitro marrow purging.
    Giarratana MC, Gorin NC, Douay L.
    Nouv Rev Fr Hematol (1978); 1995 Oct; 37(2):125-30. PubMed ID: 7644349
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Bone marrow purging in patients with refractory cancer.
    Meagher RC, Stevens DA, Herzig GP, Fay JW, Harden EA, Montes VM, Heye MM, Herzig RH.
    Prog Clin Biol Res; 1992 Oct; 377():281-7. PubMed ID: 1438426
    [No Abstract] [Full Text] [Related]

  • 18. Drug-mediated marrow purging: mafosfamide in adult acute leukemia in remission. The experience of the Italian study group.
    Rizzoli U, Mangoni L, Carella AM, Aglietta M, Porcellini A, Coleselli P, Angrilli F, Alessandrino EP, Madon E, Locatelli F.
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():190-4. PubMed ID: 2653502
    [No Abstract] [Full Text] [Related]

  • 19. The cytotoxicity of alkyl-lysophospholipid on clonogenic leukemia cells and on normal bone marrow progenitor cells is highly, but differentially, increased by cryopreservation.
    Verdonck LF, Heesbeen EC, van Heugten HG, Staal GE, Rijksen G.
    Bone Marrow Transplant; 1992 Apr; 9(4):241-5. PubMed ID: 1600412
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.